Moreover, CAR-T cells targeting MSLN were administered to patients with pancreatic ductal adenocarcinoma, malignant pleural mesothelioma and OC who participated in a phase I clinical trial (NCT02159716) [71]. The gene discussed is MSLN; the disease is malignant pleural mesothelioma.